Changes
/* Global Acne Medications Market */
[[Image:Acne marketBCC ACNE.jpg|center|thumb|center|632px * 341px|Source:BCC Research,[http://www.marketresearch.com/BCC-Research-v374/Skin-Disease-Treatment-Technologies-Global-7616658/]]]
{|border="0" cellspacing="0" cellpadding = "0" width="100%"
{|border="0" cellspacing="0" cellpadding = "0" width="100%"
|<font color="#282828"> Source: Medicines in Development for Skin Diseases 2011, [http://www.phrma.org/sites/default/files/pdf/skindiseases2011.pdf Pharmaceutical Research and Manufacturers of America</font>|-|}, 2011]
===Industry Forecast===
* Improving economic conditions is likely to drive the market, as greater disposable income growth allows consumers to spend on higher-priced over-the-counter (OTC) items.
[[Image:US ACNE2US2018 acne.jpg|center|thumb|center|632px * 341px|Source:IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html]]]
===Major Players in Acne Space===
* J&J (Neutrogena, Clean & Clear, Aveeno, Ambi) commanded over 28.8% of anti-acne preparation sales in 2012. J&J’s closest rival was Guthy Renker,(Proactiv Solutions) which had a 24.6% share followed by Reckitt Benckiser at 14.7%.
[[Image:US Acne Share2Share.jpg|US Acne Share.jpg|thumb|center|632px * 341px|Source : IBIS World International,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html]]]
===Consumer Target Group & Product Categorization===
